Evidence mapPaperPMID 41209112Full record

ReviewReviews in cardiovascular medicine2025

Lipoprotein(a) and High-Risk Coronary Plaques: Mechanisms, Characteristics, and Emerging Therapeutic Strategies.

Shuhan Fang, Chancui Deng, Ranzun Zhao

Abstract readReview
In one paragraph

Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuhan FangThe First Clinical Institute, Zunyi Medical University, 563000 Zunyi, Guizhou, China.ORCID https://orcid.org/0009-0009-9283-0709
Chancui DengDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, 563000 Zunyi, Guizhou, China.ORCID https://orcid.org/0009-0004-6377-0800
Ranzun ZhaoDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, 563000 Zunyi, Guizhou, China.ORCID https://orcid.org/0000-0002-0400-2260

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein(a) (Lp(a)) is an established independent risk factor for atherosclerotic cardiovascular disease, particularly in the development of high-risk coronary plaques (HRPs). Elevated Lp(a) contributes to lipid accumulation, vascular inflammation, and plaque instability, primarily through oxidized phospholipids that promote monocyte adhesion and foam cell formation. Genetic studies have identified variants in the

Indexed as

atherosclerosishigh-risk coronary plaqueslipoprotein(a)mechanismstherapeutic strategies

Identifiers

PMID41209112
PMCPMC12593759

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.